Industry Roundup: SEC Fines MJN, Criminal Charge For Herbals Seller, Decree Closes Aspen Supplement Marketer

FCPA violations cost Mead Johnson $12M; decree closes Aspen supplement marketer; equity funding for SmartyPants; homeopathic online retailer warned; ForeverGreen launches strong; and more news in brief.

Mead Johnson Nutrition Co. settles Securities and Exchange Commission charges concerning bribery of health care professionals in China to help drive infant formula sales, two years after China fined the firm in a price-fixing investigation. According to an SEC July 28 statement, Mead Johnson consented to an agency order on violations of the Foreign Corrupt Practices Act, without admitting or denying the findings, and agreed to pay $7.77 million disgorgement, $1.26 million in prejudgment interest and a $3 million penalty. SEC said MJN employees from 2008 to 2013 directed paying “distributor allowance” funds in cash and other incentives to hospitals in China to recommend the firm’s products and provide contact information for marketing its infant formula directly to patients. The Glenview, Ill.-based firm said its payment to SEC is in line with an expense provision it disclosed in an SEC filing earlier in 2015 related to the investigation. MJN also noted it is “taking a number of positive steps to bolster its compliance program, function and processes.” MJN paid a $33 million fine in 2013 as one of six infant formula manufacturers China’s trade regulators accused of price fixing and antimonopoly practices ([A#05140127006]).

A Montana herbal supplement seller faces a criminal contempt charge as the Department of Justice alleges the online retailer continued to sell products with claims of curing diseases despite court...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

BIOSECURE Act Returning, Privacy, Gain-of-Function Bills Coming, Senate Sponsor Says

 

Legislation prohibiting work with certain Chinese biopharma firms will be reintroduced soon, Democratic Sen. Gary Peters said. And it will not be the only bill tied to international biotech competition and security concerns that will be considered.

US FDA’s Expanded Surprise Foreign Inspections: Impact And Enforcement Hoops

 

As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.

China Plans Clinical Data Protection By Product Category For First Time

 
• By 

After almost seven years, China’s NMPA has once again published draft measures for clinical trial data protection, opening these up to public comments. While specific protection periods by drug category are proposed, some clarifications are still needed.

China Approvals Rise But Conditional-To-Full Conversion Slips

 
• By 

A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.

More from Asia

US FDA’s Expanded Surprise Foreign Inspections: Impact And Enforcement Hoops

 

As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By 

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

India Signals ‘Systemic Changes’ In CGT Regulatory Approach

 

India is pressing ahead with “big shifts” in its regulatory approach for cell and gene therapies. Reduced “layers of review”, tighter internal timelines, upcoming guidelines to facilitate CGT development and reforms in the constitution of expert committees are some of the key changes.